Clinical Trials

LymphoidOther hematologic neoplasm

49 enrolled 34 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01841736 2026-05-27

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

171 enrolled 15 charts

EndocrineNET

Neuroendocrine Tumors

NCT03213652 2026-05-27

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

13 enrolled

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03919071 2026-05-27

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

58 enrolled

CNS

Astrocytoma, Glioblastoma, Glioma

NCT04345913 2026-05-27

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

24 enrolled 24 charts

Triple Negative Breast Neoplasms

NCT04387656 2026-05-27

NCI COVID-19 in Cancer Patients, NCCAPS Study

1,877 enrolled

COVID-19, Neoplasm Metastasis

NCT05419011 2026-05-27

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

186 enrolled

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 1 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03180502 2026-05-26

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

120 enrolled

CNS

Astrocytoma, Glioma, Oligodendroglioma

NCT03793179 2026-05-26

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

600 enrolled

Lung Neoplasms

NCT06203912 2026-05-26

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

3 enrolled

Plasma cell

Multiple Myeloma

NCT01251874 2026-05-22

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

44 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02849496 2026-05-22

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

81 enrolled

Breast Neoplasms

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

11 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04595747 2026-05-22

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

48 enrolled

GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors

NCT03317392 2026-05-20

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

132 enrolled 22 charts

Genitourinary

Prostatic Neoplasms

NCT03817398 2026-05-20

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Other hematologic neoplasm

110 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT06038526 2026-05-20

Evaluation of Canakinumab in High-Risk Former-Smokers

41 enrolled

Lung Neoplasms

NCT01585805 2026-05-19

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

83 enrolled 23 charts

Pancreatic Neoplasms

NCT03030378 2026-05-19

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

36 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03367741 2026-05-19

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

82 enrolled 11 charts

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04514497 2026-05-19

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

EndocrineGastrointestinalThoracic

29 enrolled 25 charts

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04200768 2026-05-18

FATLAS

Phase NA Active not recruiting

150 enrolled

BreastOther

Breast Neoplasms, Obesity, Inflammatory Breast Neoplasms

NCT05228275 2026-05-18

Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer

549 enrolled

COVID-19

NCT02954874 2026-05-15

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03737695 2026-05-15

Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer

300 enrolled

Breast Neoplasms

NCT04042831 2026-05-15

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

32 enrolled 15 charts

Bile Duct Neoplasms

NCT01937039 2026-05-14

Johns Hopkins Breast Cancer Program Longitudinal Repository

810 enrolled

Breast Neoplasms, Cystic Fibrosis

NCT01947023 2026-05-14

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

23 enrolled

Head & Neck

Thyroid Neoplasms

NCT04708418 2026-05-14

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

60 enrolled

Melanoma

NCT05554341 2026-05-14

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

40 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT01089101 2026-05-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

217 enrolled

CNS

Astrocytoma, Neurofibromatosis 1

NCT01841723 2026-05-13

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Other hematologic neoplasm

44 enrolled

Leukemia, Hairy Cell

NCT01955499 2026-05-13

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

39 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01989585 2026-05-13

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

75 enrolled

Melanoma

NCT02160015 2026-05-13

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

LymphoidOther hematologic neoplasm

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02194738 2026-05-13

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Phase NA Active not recruiting

8,300 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02196181 2026-05-13

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

280 enrolled

Melanoma

NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

59 enrolled

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT02339571 2026-05-13

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Phase 2/3 Active not recruiting

600 enrolled

Melanoma

NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

71 enrolled

CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

152 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT02496663 2026-05-13

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

138 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02595931 2026-05-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

66 enrolled

GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT02595944 2026-05-13

ANVIL

903 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02834013 2026-05-13

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

818 enrolled

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT02862275 2026-05-13

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Other hematologic neoplasm

40 enrolled

Neoplasm Metastasis, Hematologic Neoplasms

NCT02923778 2026-05-13

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

40 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

68 enrolled

DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

NCT02997228 2026-05-13

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

120 enrolled